Mitochondria

Overview

Isolated intact, functional mitochondria harvested from UCT-WJ-MSCs; designed to restore cellular ATP production, reduce oxidative stress, and revitalize energy-depleted cells in metabolic, neurological, and cardiac conditions

Related: Stem Cells Overview

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Isolated mitochondrial preparations of this kind sit within a broader, established field of mitochondrial transplantation for therapeutic use.^[3]

Clinical Overview

Ischemic and metabolically exhausted tissue — whether hibernating myocardium, acute ischemic injury, ischemic kidney, or ischemic neural tissue — shares a terminal bottleneck distinct from the inflammatory and fibrotic pathology addressed by exosome or secretome products: damaged or depleted mitochondria that can no longer generate sufficient ATP to sustain cell survival and function, regardless of how well upstream inflammation or vascular supply is otherwise managed. This has driven a translational field of mitochondrial transplantation — replacing damaged native mitochondria with viable, respiration-competent mitochondria delivered directly into ischemic tissue — which has already reached a Phase I clinical trial in pediatric cardiac ischemia-reperfusion injury and a first-in-human trial in acute cerebral ischemia. Sourcing high-membrane-potential mitochondria from UCT-WJ-MSCs rather than the patient's own non-ischemic tissue (the autologous approach used in the pediatric cardiac trial) provides an allogeneic, off-the-shelf source of respiration-competent mitochondria, avoiding the delay and additional surgical harvest autologous sourcing requires. Akira's mitochondria are co-formulated with the exosome and secretome fractions, intended to address the bioenergetic (mitochondrial), paracrine signaling (exosome), and trophic (secretome) components of ischemic tissue recovery together.

Mechanism of Action

ATP Restoration via Oxidative Phosphorylation: Engrafted mitochondria integrate with host cell OXPHOS machinery, generating ATP via the electron transport chain (Complex I–IV and ATP synthase). Cells in bioenergetic crisis (neurons, cardiomyocytes, renal tubular cells) recover from energy failure, preventing caspase-dependent apoptosis.

Rescue of Apoptotic Cascade: Transplanted mitochondria with intact ΔΨm stabilize the mitochondrial membrane, prevent cytochrome c release, and suppress caspase-9/caspase-3 activation in cells undergoing intrinsic apoptosis — enabling recovery from lethal bioenergetic injury.

Oxidative Stress Reduction: Transplanted mitochondria augment cellular antioxidant capacity through enhanced SOD2, catalase, and glutathione peroxidase expression, reducing superoxide and H₂O₂ levels that drive mtDNA damage, lipid peroxidation, and protein oxidation.

Mitochondrial Dynamics Restoration: Young UCT-MSC mitochondria have higher fusion:fission ratio, longer, interconnected networks, and lower DRP1 activity vs. aged/dysfunctional host mitochondria. Fusion with transferred organelles 'rejuvenates' the host mitochondrial network quality.

Paracrine Signaling from Co-packaged Exosomes: The 2 mL vial also contains exosomes and secretome from parent UCT-MSCs, providing growth factors and miRNAs that amplify the direct mitochondrial bioenergetic effect with anti-inflammatory and pro-survival paracrine signals.

Key Biomarkers & Molecular Cargo

Potential Applications

• Cardiac Hibernation / Ischemic Heart: mitochondrial donation restores ATP production in energy-depleted, functionally hibernating cardiomyocytes.
• Acute Ischemic Injury: ATP restoration in energy-depleted cells via tunneling nanotube and vesicle-packaged mitochondrial transfer.
• Ischemic Kidney Tissue: mitochondrial transplantation restores oxidative phosphorylation in renal tubular cells, reduces ischemia/reperfusion-induced apoptosis, and supports the regenerative potential of injured tubules.
• Ischemic Neural Tissue: intra-arterial mitochondrial delivery elevates ATP concentration in ischemic brain parenchyma, reduces infarct volume, and supports post-stroke neurogenesis in preclinical models.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

A Phase I pediatric cardiac trial delivered autologous mitochondria into ischemia-reperfusion-injured myocardium in ECMO-supported children — a first-in-human milestone demonstrating safety and improved myocardial function, and the first clinical proof that direct mitochondrial delivery is feasible and beneficial in ischemic human tissue.^[4]

A Phase I trial in acute cerebral ischemia delivered autologous mitochondria via intra-arterial injection following mechanical thrombectomy, reporting safety and feasibility.^[5] This builds on preclinical rodent stroke models where intra-arterial or intraventricular mitochondrial delivery reduced infarct volume, decreased oxidative stress and apoptosis, and improved neurological outcomes.^[6]

In rodent and large-animal (pig) kidney ischemia-reperfusion models, intra-arterial or systemic IV mitochondrial transplantation prevented renal tubular cell death, restored renal function, and decreased ischemia/reperfusion-induced apoptosis.^{[7] [8]}

Across cardiac, cerebral, and renal ischemic contexts, only a small fraction of the isolated mitochondrial suspension volume was needed for measurable protective benefit, with localized/regional delivery routes associated with a lower required dose than systemic administration.